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Introduction. Breast cancer is the most common cancer in women – both in Poland and around the world. In terms of 
the mortality rate, it subsides  brest cancer with lung cancer. In 2018, almost 2 million new cases were reported worldwide, 
and almost 44 million women have been diagnosed with breast cancer in the last 5 years.
Material. The aim of this paper is to present ways to improve the sexual well being of breast cancer patients.
Methods. Analysis of the literature by oncologists, gynecologists, and psychologists was used for theoretical discussion. 
Results. Sexuality is an extremely important part of every woman’s life, including those suffering from breast cancer. 
Surgery of the breast, a symbol of a woman’s sexuality, and the negative effects of cancer therapy can alter a woman’s 
perception of her own body and lower her libido. Sexual therapy which should be based on multi-faceted activities, is an 
extremely important part of breast cancer treatment. 
Conclusions. Therapeutic possibilities may be based on psychological and sexual therapies as well as pharmacological 
support (moisturizers, silicone lubricants, tampons inserted for several minutes with 4% vaginal lidocaine before intercourse, 
topical gels with estrogens, ospemifen, DHEA, testosterone). 
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Introduction
Breast cancer is the most common cancer in women in Poland 
and around the world. In terms of the mortality rate, it subsides 
breast cancer with lung cancer. In 2018, almost 2 million new 
cases were reported worldwide, and almost 44 million women 
have been diagnosed with breast cancer in the last 5 years [1]. 
Early and modern diagnostics as well as effective treat-
ments have improved the prognosis of women with breast 
cancer, i.e. increasing the time of total survival and improving 
the overall quality of life. The majority (about 70–80%) of bre-
ast cancers show expression of hormonal (estrogen and/or 
progesterone) receptors, about 15–20% are cancers showing 
an overexpression of the HER2 receptor or amplification of its 
gene, about 15% are the worst case prognoses – the so-called 
triple negative (without expression of hormonal receptors and 
an overexpression of the HER2 receptor). The expression of 
hormonal receptors has a predictive meaning, conditioning 
treatment that inhibits or significantly reduces the level of 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
233
sexual hormones. The treatment is usually applied by patients 
for 5–10 years. 
Chemotherapy is used in most patients with triple ne-
gative and HER2-positive breast cancer, also occasionally in 
patients with hormone dependent breast cancer. Side effects 
of chemotherapy appear early in the course of treatment, such 
as nausea, vomiting, diarrhea, alopecia; some, after weeks, 
months or years of therapy – cardiomyopathy, myelodysplastic 
syndrome, or secondary malignancies.
Sexuality is an extremely important part of every woman’s 
life, including those suffering from breast cancer. Surgery of the 
breast, a symbol of a woman’s sexuality, and the negative effects 
of cancer treatment alter a woman’s perception of her own body 
and lower her libido. The aim of this paper is to present ways to 
improve the sexual well being of breast cancer patients.
Influence of systemic treatment on premature 
cessation of ovarian function
Up to 1/3 of women with recently diagnosed breast cancer, men-
struate when the cancer is diagnosed. Chemotherapy causes pre-
mature cessation of ovarian function in about 30–40% of women 
under 40 years of age, and even in 90% of women over 40 years of 
age. In 90% of women under 35 years of age, menstruation only 
returns up to 2 years after the end of chemotherapy [2].
Approximately 64% of premenopausal women complain 
of hot flashes or night sweats during or after treatment, 42% 
of them have vaginal atrophy, 29% of them have osteoporosis, 
28% even think about discontinuing breast cancer hormonal 
treatment because of the accompanying symptoms. Studies 
show that almost 1/3 of these women have never been asked 
by their physician about the possible presence of vasomotor 
symptoms (hot flashes, sweats, increased blood pressure) [3].
The symptoms caused by menopause induced by cancer 
treatment are usually exacerbated. Physiological menopause 
is a long-term process, which is slow for many months, while 
menopause induced by cancer therapy often affects young 
patients experiencing a decrease in sexual hormone levels 
within a short time, even overnight. The changes in the body 
can be rapid and the symptoms rather troublesome.
Influence of systemic treatment on fertility
Extra attention is also being paid to reproductive issues. Wo-
men want to be mothers and enjoy motherhood, despite their 
cancer. Current anticancer treatments have a significant impact 
on a woman’s reproductive abilities.
Over the years, women have been deciding to have of-
fspring later. Now the average age of a European woman at the 
birth of her first child is 39 years. Subsequently, a breast cancer 
diagnosis can appear before or during a woman’s procreation 
plans. Systemic treatment can not precipitate the cessation of 
ovarian function, but also postpone the moment when it is 
possible and safe to become pregnant. Pregnancy after breast 
cancer treatment is possible and safe. 
Every woman of childbearing age should be informed 
about the side effects of treatment as well as the possibility 
of using fertility preservation techniques; they can also be 
referred to a reproductive medicine specialist before starting 
cancer treatment. The most commonly used techniques with 
proven effectiveness include: the collection and freezing of 
oocytes or embryos. The choice of an appropriate method 
depends on age, a woman’s ovarian reserve, and the planned 
oncological treatment.
It is worth taking care to maintain fertility before cancer 
treatment, which will make a woman’s life more comfortable. 
Sex need not only be a way to get pregnant, but can also be 
a source of pleasure.
Reproduction after breast cancer
Indeed, for many young women, the possibility of having 
children after completing cancer treatment is significant. Of co-
urse, a decision about pregnancy may be challenging and 
problematic due to prevailing myths and distortions regarding 
the safety of the future mother’s pregnancy, the impact of che-
motherapy on the fetus and the child, and breastfeeding issues. 
A breast cancer diagnosis is usually accompanied by shock, 
fear, disbelief, anxiety, and high-stress levels. Hence, patients 
accumulate all their thoughts around treatment, rejecting 
decisions related to functioning, fertility, and motherhood 
after treatment. After undergoing anticancer treatment, the 
possibility of becoming pregnant may be significantly limited 
or completely unavailable. This is caused by the toxic effects 
of drugs on the gonads [4–6]. 
Young female patients, premenopausal, who became sterile 
due to anticancer treatment, may experience many psychologi-
cal difficulties, including depression. In addition, some patients 
may experience intense fear and the fear of a recurrence of the 
disease and related problems or e.g. the inability to raise a child. 
This fear can be so overwhelming that some women stop trying 
to get pregnant. Therefore, it is worth emphasizing the role of 
psychological counseling therapy, and the benefit of support 
from a psycho-oncologist or sexologist who can help women 
and their partners make the right decisions, and choose the best 
solutions during diagnosis and post-treatment [7–9].
Unfortunately, it still happens all too often that physicians 
do not sufficiently and adequately inform patients at the time 
of diagnosis about the possibility of preserving fertility. Such 
inconsistent and hard communication with the patient causes 
frustration and anger and is associated with increased stress. 
Therefore, it should be remembered how vital motherhood is, 
for it can be a significant element in aiding women’s psycho-
logical rehabilitation after breast cancer treatment.
The influence of surgical treatment on the 
perception of one’s body
Breast cancer and the methods involved in its treatment have 
a very important impact, not only on somatic health or the 
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patients’ quality of life, but above all on the extremely im-
portant psychological and sexual sphere, as well as on the 
attitude to one’s body. This is particularly evident in the case 
of a one-sided or two-sided mastectomy, which changes the 
way patients perceive, feel, and experience emotional, social, 
and family life. Surgical treatment of cancer causes a woman 
to start perceiving their body differently. In addition, the sense 
of aesthetics deteriorates and there is increased restraint of 
women body, which undoubtedly has a significant impact on 
one’s awareness of beauty and self-esteem, causing a disparity 
between the idealized, sexually attractive image of a woman 
ubiquitous in popular media, and the body of a cancer patient 
after treatment [10–12].
The process of cancer treatment has a significant impact 
on the patient’s quality of life, as well as on the satisfaction 
level of sexual well being. Unfortunately, the sexual aspect 
is still often neglected, without due diligence. Sexuality is 
one of the important components of general health and 
quality of life. 
The Declaration of Human Sexual Rights established by the 
World Sexual Health Organization (2014) [13] assumes that: 
"Sexuality is a key aspect of a person’s life throughout its entire 
duration and includes gender, roles and sexual identities (socio-
-cultural gender-related), sexual orientation, eroticism, pleasure, 
intimacy and reproduction. Sexuality is experienced and expres-
sed in the form of thoughts, fantasies, desires, beliefs, attitudes, 
values, behaviors, practices, roles and relationships. Sexuality 
can include all of the above, but not all of its dimensions must 
be experienced or expressed. Human sexuality is influenced by 
complex biological, psychological, social, economic, political, 
cultural, legal, historical, religious and spiritual factors".
Of course, the psychological aspect, emotional sphere, 
or sense of attraction for the patient’s partner should not be 
omitted here; this undoubtedly affects the quality of one’s 
sexual life, as it is associated with self-esteem, a sense of self-
-respect, and an acceptance of the body that was changed 
by the cancer. According to Zdończyk S.A. [14], women after 
cancer surgery show a worryingly low self-esteem as sexual 
partners. Therefore, it seems appropriate to rationally approach 
this type of disorder.
The psychophysical condition and psychological well-
-being of a breast cancer patient are often very unsatisfactory. 
Their reduced level of self-esteem  and the presence of the 
disease are often the main factors that cause sexual disorders. 
The patient’s approach to their own body, sexuality, well-being, 
sense of attraction, and relationship with their partner are all 
extremely important. If before surgery, the patient had a low 
opinion of their attractiveness, and exhibited low self-esteem, 
these feelings will be all the more exacerbated after treatment. 
Many women struggle with the so-called half-woman complex 
– the loss of one breast, the resulting asymmetry of the body, 
scarring; these are all reasons for a serious reduction in the 
level of one’s visual self confidence regarding appearance [15]. 
In addition to the patient’s lack of self confidence, their 
mood or depression, which may develop during the cancer 
and cancer treatment process, is also worth noting. In such 
a case, the therapy to combat depression should be under-
taken with the appropriate diagnosis. The socio-cultural stan-
dards of beauty, ubiquitous sexuality, and the perfect ideal of 
woman’s body present in the mass media are also important 
factors that may speed up the development of these disorders. 
Patients often feel that sex is unnatural, forced, and often 
involves internal compulsion. The woman feels guilty of her 
indisposition, her attitude begins to become more restrictive, 
until she finally gives up on sexual activity completely.
Sexual satisfaction
It is safe to say that sexual satisfaction is largely related to the 
quality of relationship in which the woman realizes herself 
sexually. Furthermore, the satisfaction that results from sexual 
intercourse should be considered a vital element of any suc-
cessful original meaning [16]. There is no doubt that sexual 
satisfaction is a very important element of sexual activity. It is 
recognized as an important indicator of health in the sexual 
sphere, as well as an exponent of well being and quality of life; 
a satisfying sex life determines both the quality and endurance 
of a partnership [17, 18]. 
The frequency of initiated behaviors and sexual activities 
is associated with sexual satisfaction and, consequently, the 
satisfaction of a partnership or marriage [19, 20]. The forms of 
breast cancer treatment, and the methods used are often very 
aggressive, subsequently causing a number of inconveniences 
and side effects. These include, among others, sexual disorders, 
which significantly reduce the state of one’s sexual health. 
The patient feels a recurring problem of a sexual nature, and 
discomfort and dissatisfaction with sexual activity [21]. There 
are four basic categories of sexual disorders in women:
• reduced desire – a reduction or loss of interest in sexu-
al issues, images related to sexual activity, a reduction 
of feelings of desire and thoughts regarding sex-related 
matters, 
• sexual arousal disorders – the genital response is insuffi-
cient in terms of lack of vaginal lubrication and inadequate 
swelling of the lips of the vulva, 
• orgasm disorders – associated with an orgasm dysfunction, 
its delay or complete absence,
• dyspareunia – permanent or recurring pain of the genitals 
occurring during the course of penis penetration into the 
vagina throughout intercourse (including during a gyne-
cological examination).
Sexual dysfunctions resulting from cancer treatment may 
have serious consequences and significantly affect the pa-
tient’s quality of life, their relationship with a partner, psycho-
logical difficulties. They may cause the patient to avoid sexual 
intercourse, in addition, there may be unpleasant associations 
with sexual activity, or shifting the blame to the partner, which, 
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in turn may lead to a complete breakdown of their intimate 
relationship.
It should be clearly emphasized that patients treated for 
breast cancer experience a decrease in physical activity and 
satisfaction with their sexual life. In addition, desire disorders, 
orgasm problems, breast sensation disorders, vulvovaginal 
atrophy, menopausal symptoms appear (hot flashes, sweating, 
fatigue, joint and muscle pains, irregular menstruation, irrita-
bility, intimate infections, weight loss), or lubrication disorders 
[13, 22]. 
Pain associated with sexual activity results in a negative 
attitude towards sexuality, and thus increases the impairment 
of sexual function. Patients with dyspareunia are accompa-
nied by reduced frequency of sexual intercourse and are less 
enthusiastic about initiating this type of behavior. They also 
have a reduced desire level, excitement is diminished, with less 
intense feelings of orgasm during intercourse  [23].
Sexual therapy
The issue of women’s sexuality after breast cancer treatment 
still seems taboo. It is possible to observe an increased number 
of publications devoted to this subject, but this is still insuffi-
cient. Patients, their families, and even medical staff often feel 
too much embarrassment and shame to report problems, 
with regards to the prospect of discussing the diagnosis and 
analyzing the sexual concerns that arise. There is still an inner 
conviction that compared to the grave severity of cancer, 
which is a real threat to life, the subject of possible sexual 
dysfunction is trivialized.
Sexual therapy, which should be based on multi-faceted 
activities, is an extremely important process that has a key role: 
• first stage – conversation with the patient about the pro-
blem in the sexual sphere related to the disease or its 
treatment, 
• second stage – gathering as much knowledge as possible 
about the problem, its origin, details and aspects of the 
patient’s sexual life by the physician, 
• third stage – detailed suggestions, i.e. conversation/con-
sultation with specialists in the field of sexology, psycho-
logy or oncology based on an individual approach to the 
problem, 
• fourth stage – intensive care for patients who require it 
or who have been recommended, which may include 
psychotherapy, pharmacological therapy or surgery [24].
Pharmacological treatment
Problems during intercourse can be permanent or recurring. 
They may appear during penetration or intercourse. They may 
even arise earlier as a fear of penetration or intercourse, and the 
associated tension and tightening of the pelvic floor muscles.
Treatment must first start with awareness and discussion of 
the problem. If there is openness in the relationship, the partner 
should also be involved in the treatment. The patient should be 
listened to but also be aware that the range of standards and 
expectations of sexuality are very different, not only between 
people, but even during the individual process of puberty, ma-
turity, and aging. The disease, and especially the treatment of 
the disease, will have a significant impact on the leap in sexual 
stimulation and excitement curve that is appropriate for the 
patient. Expectations about the necessity of intercourse may 
also be relative. However, if penetration is expected, additional 
measures to increase comfort and facilitate sexual activity 
are desirable. The definition of expected sexual satisfaction 
is a reference point for proposing further treatment. Based 
on the diagnosed problems and expectations, individualized 
treatment should be chosen.
Therapeutic possibilities may be based on psychological 
and sexual therapies as well as pharmacological support. Tre-
atment of physical problems during intercourse can be based 
on an algorithm of gradually increasing the invasiveness of tre-
atment, depending on the difficulty of obtaining the expected 
effect [25]. In the first stage, moisturizers are proposed, while 
opinions about lubricants are more ambiguous. Using the 
former in doses larger than standard, achieves good vaginal 
lubrication and a transient positive effect during intercourse 
[26]. If a positive effect is obtained, its stability should be veri-
fied and the treatment in case of its loss should be modified. 
In case of further problems with the use of maximum amounts 
of silicone lubricants, it is proposed to use tampons for several 
minutes  before intercourse with 4% vaginal lidocaine. 
In the next stage, the use of topical gels with estrogens 
in minimal doses may be considered. As both opinions and 
published data on the potential risk of steroid use in patients 
treated for breast cancer are divided [27], a decision on hor-
mone treatment should be made together with the patient. 
Approximately 30–50% of women opt for estrogen treatment 
under medical supervision [28]. Some of them would also 
accept an increase of 1/3 of the risk of relapse, if the treatment 
resulted in cessation of symptoms [29]. It is assumed that 
doubling the level of estradiol in the blood increases the risk 
of relapse by about 1/3 [30]. Therefore, estradiol levels should 
oscillate within this range.
There is no direct correlation between serum estrogen 
levels and the resolution of symptoms associated with vaginal 
atrophy, thus the dose should be adjusted to the quality of 
vaginal mucosa and function required. The period of epithelial 
regeneration under the influence of hormones takes about 
4 weeks. During this period, estrogens more easily penetrate 
the atrophic vaginal mucosa into the bloodstream. Therefore, 
minimum doses should be used to rebuild the vaginal epi-
thelium at the expense of prolonging its regeneration time.
It is also worth noting that most breast cancer patients 
with hormone receptor expressions use tamoxifen or aro-
matase inhibitor based therapy for 5–10 years. Tamoxifen is 
an estrogen receptor modulator (selective estrogen receptor 
modulator – SERD), it stimulates or blocks its activity, depen-
236
ding on its location in the body. Aromatase inhibitors inhibit 
the aromatization of androgens to estrogen primarily in the fat 
tissue, inhibiting their production, but without affecting the 
effects of estrogen on the receptor. Due to their mechanism of 
action (aromatase inhibitors), it seems that for those patients 
who use tamoxifen, the vaginal estrogen effect will be mainly 
limited to topical effects.
Among the possible estrogens to use, the selective es-
trogen receptor modulator ospemifen should be mentioned. 
It is recommended in post-menopausal women with severe 
symptoms: dryness and vaginal atrophy. Due to its beneficial 
effect profile, it is not contraindicated in women with breast 
cancer after the completion of adjuvant therapy [31].
The use of DHEA is also considered both orally and vaginal-
ly. In both cases, this treatment seems to reduce the symptoms 
of vaginal atrophy and improve sexual function without incre-
asing estrogen levels above the expected levels [32]. The use 
of testosterone is more controversial. It improves satisfaction 
from intercourse, increases libido, improves mood and general 
well-being, but there are no clear data on the safety of its use 
in women who are being treated for breast cancer [33].
It is extremely important to educate patients to be open 
to conversations related to sexuality in order for them to enjoy 
life to the fullest, despite the disease, and to feel satisfaction 
and contentment. It is worthwhile informing patients abo-
ut available methods and strategies for dealing with sexual 
dysfunction. Providing basic knowledge on how to properly 
lubricate vaginal walls before sexual intercourse with the use 
of water or silicone based lubricants, as well as the systematic 
use of vaginal globules or gel applications with hyaluronic acid 
can significantly contribute to improving the sex life of women.
It is also worth referring the patient to a urogynelogical 
physiotherapist, in order to stimulate the blood supply to 
the genitals through the use of appropriate relaxation exercises 
for vaginal muscles.
Conclusions
Sexual activity and performance are extremely important in 
human life. Treatment of breast cancer certainly has a negative 
impact on a patient’s emotional state, their mental state, but 
also on the sexual satisfaction and intimate relations with 
a partner [34]. Patients treated with breast-conserving therapy 
are still relatively few in Poland [35]. Proper breast oncology 
surveillance during pregnancy, using safe and inexpensive 
methods including ultrasonography and biopsy of suspicious 
masses, can ensure the prevention of cancer development 
and progression [36]. The stage of the disease at diagnosis is 
also a major prognostic factor in pregnancy-related cervical 
cancer [37].
Sexual dysfunctions may also occur after treatment is 
completed, which is undoubtedly associated with a decrease 
in satisfaction and contentment resulting from a decrease in 
the quality of intimate relationships. Unfortunately, in most 
cases, women are not informed about the possibilities of de-
aling with this problem. The diagnosis and consequences of 
treatment affect intimate relationships [38]. Relationship with 
one’s partner is a very important factor that determines the 
psychosocial health of patients. 
Unfortunately, women’s knowledge of changes in their 
body during the disease and their knowledge of solutions to 
sexual disorders is still inadequate. Patients are ashamed to talk 
to an oncologist about sexuality or dysfunctions that have 
arisen as a result of oncological treatment. Zdończyk (2015) 
points out that there is still a big taboo evident; a barrier is 
created by shame, lack of trust from the patient, ignorance of 
proper terminology, and a basic lack of openness or empathy 
from the physician. All this is further exacerbated by the lack 
of sufficient time and knowledge of physicians or other health 
care representatives.
It is worth noting that the subject of sexuality of patients 
treated for breast cancer is becoming more discussed. This pa-
per does not exhaust the entire subject, and the area of issues 
could be more detailed with regard to the psychophysical 
difficulties associated with the disease, as well as the various 
approaches to the subject of the disease and the disorders 
resulting from it, along with the communication problems 
between the patient and the health service.
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